公开(公告)号：EP3067364A3

公开(公告)日：2016-12-07

申请号：EP16151097.9

申请日：2011-11-17

申请人： Novartis AG

发明人： Boettcher, Brian R. ,  Caplan, Shari Lynn ,  Daniels, Douglas S. ,  Geierstanger, Bernhard Hubert ,  Hamamtsu, Norio ,  Licht, Stuart ,  Loew, Andreas ,  Weldon, Stephen Craig

IPC分类号： C07K14/50 ,  A61K47/48 ,  A61K38/18

CPC分类号： A61K38/1825 ,  A61K47/593 ,  A61K47/60 ,  C07K14/50 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/31

摘要： The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.

公开(公告)号：EP3067364A2

公开(公告)日：2016-09-14

申请号：EP16151097.9

申请日：2011-11-17

申请人： Novartis AG

发明人： Boettcher, Brian R. ,  Caplan, Shari Lynn ,  Daniels, Douglas S. ,  Geierstanger, Bernhard Hubert ,  Hamamtsu, Norio ,  Licht, Stuart ,  Loew, Andreas ,  Weldon, Stephen Craig

IPC分类号： C07K14/50 ,  A61K47/48 ,  A61K38/18

CPC分类号： A61K38/1825 ,  A61K47/593 ,  A61K47/60 ,  C07K14/50 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/31

摘要： The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.